Traditional East Asian Herbal Medicine for Amyotrophic Lateral Sclerosis: A Scoping Review.
Journal
Evidence-based complementary and alternative medicine : eCAM
ISSN: 1741-427X
Titre abrégé: Evid Based Complement Alternat Med
Pays: United States
ID NLM: 101215021
Informations de publication
Date de publication:
2021
2021
Historique:
received:
06
05
2021
accepted:
03
11
2021
entrez:
16
12
2021
pubmed:
17
12
2021
medline:
17
12
2021
Statut:
epublish
Résumé
This study aimed to analyze and summarize the existing evidence regarding herbal medicine treatments for amyotrophic lateral sclerosis (ALS). Studies on herbal medicine treatment in patients with ALS were searched within English, Chinese, Japanese, and Korean databases up to July 31, 2021. In the selected studies, we collected the following information: the first author, year of publication, country, language, study methodology, sample size, demographic characteristics of the study participants, disease duration, diagnostic criteria, treatment method, treatment periods, evaluation tools, results, and side effects. The organized data were classified and analyzed narratively. This study included 59 studies. The first clinical study on the effect of herbal medicine was published in 1995; moreover, most studies were conducted in China. Among the 59 selected studies, 47.5% were observational studies, including case reports and case series. Moreover, there was one meta-analysis. The El Escorial criteria were the most commonly used diagnostic criterion for ALS; moreover, the ALS functional rating scale was the most common evaluation tool. Buzhongyiqitang, Sijunzitangjiawei, and Jianpiyifeitang were the most commonly used herbal medicines, with anti-inflammatory, protein aggregation, and anti-oxidant effects. There remain evidence of gaps in the effectiveness of herbal medicine for ALS. To allow effective treatment of patients with ALS using herbal medicine, large-scale and rigorously designed high-quality clinical studies should be performed.
Identifiants
pubmed: 34912464
doi: 10.1155/2021/5674142
pmc: PMC8668313
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
5674142Informations de copyright
Copyright © 2021 Won Joo Suh et al.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest regarding the publication of this paper.
Références
Biomed Pharmacother. 2017 Dec;96:854-864
pubmed: 29078263
J Neurol Sci. 1999 Oct 31;169(1-2):13-21
pubmed: 10540002
Evid Based Complement Alternat Med. 2013;2013:613596
pubmed: 24363770
Integr Med Res. 2019 Dec;8(4):234-239
pubmed: 31692669
J Neurol Neurosurg Psychiatry. 2010 Apr;81(4):385-90
pubmed: 19710046
Evid Based Complement Alternat Med. 2013;2013:347525
pubmed: 24093046
Evid Based Complement Alternat Med. 2019 Jul 25;2019:4217057
pubmed: 31428170
Arch Neurol. 2001 Mar;58(3):512-5
pubmed: 11255459
Neurology. 2006 Jan 24;66(2):265-7
pubmed: 16434671
Curr Opin Neurol. 2019 Oct;32(5):771-776
pubmed: 31361627
Medicine (Baltimore). 2016 Apr;95(14):e3324
pubmed: 27057909
J Neurol Sci. 2001 Oct 15;191(1-2):151-4
pubmed: 11677007
Asian Nurs Res (Korean Soc Nurs Sci). 2019 Dec;13(5):287-294
pubmed: 31756513
Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293-9
pubmed: 11464847
Am Fam Physician. 1999 Mar 15;59(6):1489-96
pubmed: 10193591
Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(3-4):191-7
pubmed: 26735587